Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Respiratory Research

Fig. 1

From: Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)

Fig. 1

Flow chart of the study (CONSORT). a The reasons for not performing bilateral treatment were death before second treatment (n=1), anaphylactic shock at induction of anesthesia for the second coil treatment (n=1) (further analyses demonstrated allergy to penicillin), and pneumonia after the first coil treatment leading to unwillingness of the patient to undergo a second coil treatment (n=1). Two patients with unilateral coil treatment at 3-month follow-up were treated with a contralateral coil treatment at 12 and 18 months post-randomisation. b These two patients were alive at 12 months, but did not come for the planned visit at 12 months, and were considered for subsequent assessment at 24 months. c Bilateral treatment not performed because of pneumothorax (n=1), pneumonia (n=2) or death (n=1). One patient was treated with a contralateral coil treatment at 27 months post first treatment. d One systolic pulmonary artery pressure > 50 mmHg and one anticoagulant therapy which could not be stopped for coil treatment and also active smoking.e 1 patient moved abroad and two patients refused to come back for the follow-up

Back to article page